Does sex influence the impact that smoking, treatment interruption and impaired pulmonary function have on outcomes in limited stage small cell lung cancer treatment?

Canadian Respiratory Journal

Volumn 12, Issue 5, 2005, Pages 245-250

  Videtic, Gregory M M ^a   Truong, Pauline T ^b   Ash, Robert B ^c   Yu, Edward W ^c   Kocha, Walter I ^c   Vincent, Mark D ^c   Tomiak, Anna T ^d   Dar, A Rashid ^c   Whiston, Frances ^c   Stitt, Larry W ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d Cancer Centre of South Eastern Ontario   (Canada)

Author keywords

Chemoradiotherapy; Limited stage; Prognosis; Sex; Small cell lung cancer

Indexed keywords

CARBON MONOXIDE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; VINCRISTINE;

ADULT; AGED; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DEHYDRATION; DYSPHAGIA; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG DIFFUSION CAPACITY; LUNG DISEASE; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NAUSEA AND VOMITING; NEUTROPENIA; NUTRITIONAL DISORDER; PAIN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; REVIEW; SEPSIS; SEX DIFFERENCE; SKULL IRRADIATION; SMOKING; SMOKING CESSATION; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 25844469192     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2005/376404     Document Type: Review

References (28)

1. Sherman CA, Rocha Lima CMR, Turrisi AT III. Limited small-cell lung cancer: A potentially curable disease. Oncology (Huntingt) 2000;14:1395-403.
2. Murray N. Small-cell lung cancer at the millennium: Radiotherapy innovations improve survival while new chemotherapy treatments remain unproven. Clin Lung Cancer 2000;1:181-90.
3. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993;11:336-44.
4. Turrisi AT III, Kyungmann K, Blum R, et al. Twice-daily compared with one-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-71.
5. Takada M, Fukuoka M, Kawahara K, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small cell-lung cancer: Results of the Japan Clinical Oncology Group study 9104. J Clin Oncol 2002;20:3054-60.
6. Jeremic B, Shibamato Y, Acimovic L, et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study. J Clin Oncol 1997;15:893-900.
7. Feld R, Sagman U, Leblanc M. Staging and prognostic factors for small cell lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD, eds. Lung Cancer - Principles and Practice. Philadelphia: Lippincott-Raven, 2000:612-27.
8. Videtic GM, Fung K, Tomiak AT, et al. Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control. Lung Cancer 2001;33:249-58.
9. Videtic GMM, Stitt LW, Dar AR, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 2003;21:1544-9.
10. Videtic GMM, Stitt LW, Ash RB, et al. Impaired diffusion capacity predicts for decreased treatment tolerance and survival in limited stage small cell lung cancer patients treated with concurrent chemoradiation. Lung Cancer 2004;43:159-66.
11. Johnson BE, Steinberg SM, Phelps R, Edison M, Veach SR, Ihde DC. Female patients with small cell lung cancer live longer than male patients. Am J Med 1988;85:194-6.
12. Wolf M, Holle R, Hans K, Drings P, Havemann K. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): The role of sex as a predictor for survival. Br J Cancer 1991;63:986-92.
13. de Wet M, Falkson G, Rapoport BL. Small cell lung cancer: Analysis of factors influencing the response to treatment and survival. Oncology 1994;51:523-34.
14. Christodolou C, Pavlidis N, Samantas E, et al. Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study. Anticancer Res 2002;22:3749-57.
15. Spiegelman D, Maurer LH, Ware JH, et al. Prognostic factors in small-cell carcinoma of the lung: An analysis of 1521 patients. J Clin Oncol 1989;7:344-54.
16. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: An analysis of the 2580-patient Southwest Oncology Group data base. J Clin Oncol 1990;8:1563-74.
17. Mennecier B, Lebitasy MP, Moreau L, et al. Women and small cell lung cancer: Social characteristics, medical history, management and survival: A retrospective study of all the male and female cases diagnosed in Bas-Rhin (Eastern France) between 1981 and 1994. Lung Cancer 2003;42:141-52.
18. Murray N, Hadzic E, Shah A, et al. Alternating chemotherapy and thoracic irradiation with concurrent cisplatin-etoposide for limited stage SCLC. Proc Am Soc Clin Oncol 1984;3:321a.
19. Martinez FJ, Paine R III. Medical evaluation of the patient with potentially resectable lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, eds. Lung Cancer - Principles and Practice. Philadelphia: Lippincott-Raven, 1996:511-36.
20. Turrisi AT III, Withers HR III. Radiotherapy in limited small cell lung cancer: Fractionation and timing of modalities. Semin Radiat Oncol 1995;5:50-56.
21. Videtic GM, Truong PT, Dar AR, Yu EW, Stitt LW. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: A single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation. Int J Radiat Oncol Biol Phys 2003;57:709-16.
22. McCann J. Gender differences in cancer that don't make sense - or do they? J Natl Cancer Inst 2000;92:1560-2.
23. Commentary: Women and Smoking: A report of the Surgeon General. Oncology (Huntingt) 2003;17:453.
24. Payne S. 'Smoke like a man, die like a man?': A review of the relationship between gender, sex and lung cancer. Soc Sci Med 2001;53:1067-80.
25. Maasberg M, Rotsch M, Jaques G, Enderle-Schmidt U, Weehle R, Havemann K. Androgen receptors, androgen-dependent proliferation, and 5 alpha-reductase activity of small-cell lung cancer cell lines. Int J Cancer 1989;43:685-91.
26. Taggart DP, Gray CE, Bowman A, Faichney A, Davidson KG. Serum androgens and gonadotrophins in bronchial carcinoma. Respir Med 1993;87:455-60.
27. Tseng JE, Rodriguez M, Ro J, Liu D, Hong WK, Mao L. Gender differences in p53 mutational status in small cell lung cancer. Cancer Res 1999;59:5666-70.
28. Kaiser U, Hofmann J, Schilli M, et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer 1996;67:357-64.